The Real Cost of Compounded Semaglutide

Because five is how many routes to compounded semaglutide we have verified against a provider's own pricing page. Seven providers have been researched first-party for this site; four of them sell compounded semaglutide. Hers and Ro sell branded Wegovy, which is FDA-approved semaglutide from Novo Nordisk rather than a compounded preparation — Hers no longer offers a compounded GLP-1 at any price. Calibrate sells coaching and insurance navigation and does not sell the drug at all; its own footnote says prescription medications are not included in the membership. Noom's second compounded product never names its molecule, so only the one it does name is here. This is not every provider that exists — it is every provider whose price we have checked, and a padded board would be a longer page and a worse one.

Because it multiplies by however many times a provider actually bills, and on this board that genuinely differs. Noom prices a "12 week subscription" at "$179 per month" — three of its months make twelve weeks, so a Noom month is four weeks long and a year holds thirteen of them. Multiplying $179 by twelve gives $2,148; billing it thirteen times gives $2,327, and that $179 gap is one entire extra charge that no "per month" figure will ever show you. The effect is visible one row apart: Mochi at $178 and Noom at $179 are a dollar apart on the walk-away price and $191 apart over a year. The other four rows bill on the calendar month, so they use twelve — the arithmetic is printed under each figure so you can check which is which rather than take it on trust.

Because Strut only ever publishes one number for each of its semaglutide products, and we are not going to invent the other. Each page prints the figure twice — "As low as $99/mo" (or $149) beneath a "Save 21%" / "Save 13% with auto-refill" badge, and again as a flat 30-day price under the heading "Simple, Transparent Pricing." If those discount badges are real, the price without a standing order is higher, and Strut never states it. We could have divided $99 by 0.79 and printed $125, but that is a price no Strut page has ever shown and no reader has ever been charged. So both columns carry the figure Strut actually publishes, and the gap in Strut's own disclosure is written on the row instead of being filled in with arithmetic. Its two tirzepatide pages, by contrast, do publish both numbers.

Because the two columns measure different things, and the gap between them is the whole reason this board exists. Noom advertises $49 — by some distance the lowest number on the page — and lands fourth by walk-away price at $179, because $49 buys a three-week starter subscription and the ongoing rate is roughly three and a half times it. Found advertises $169 and costs $289, because $169 is a twelve-month plan paid up front, $2,028 charged on day one. Sorting on the advertised column would have put Noom first and Strut's genuinely cheapest $99 lozenge second; sorting on what you actually pay puts the $99 first, where it belongs.

Because it sells two different semaglutide formulations at two different prices, and both are real. The oral lozenge is $99 for a 30-day supply; the injectable, compounded with vitamin B6, is $149. Averaging them would produce a number Strut does not charge, and showing only one would hide a price you can actually buy. Since this board sorts on walk-away price alone, the two land in different places — which is the honest result, not a duplicate.

Because Found sells one plan that covers either molecule at the same price, so it is a real option for a reader pricing semaglutide and a real option for a reader pricing tirzepatide. Its own comparison tables answer "Price stays the same at every dose" with "Yes — one flat price" for compounded semaglutide and compounded tirzepatide alike, and its pricing FAQ says compounded medications are included in the cost of both plans. What Found does not publish is a semaglutide-specific figure, so $289 should be read as the price of the programme rather than a quote for the drug. Leaving it off would have hidden an option; listing it without that caveat would have implied a precision Found does not offer.

No, and that is why they are not on this board. Wegovy and Ozempic are FDA-approved semaglutide products from Novo Nordisk. A compounded semaglutide is prepared by a state-licensed compounding pharmacy and is not FDA-approved or evaluated for safety, effectiveness or quality — Noom's own footnote says "Medications are not reviewed by FDA for safety, efficacy, or quality," and Strut's weight-loss pages lead with the same disclaimer. The FDA has also written to companies in this category, including Hims & Hers in September 2025, over marketing that implied a compounded product was the same as the approved one. The two are priced in different worlds — Hers charges $298 a month all-in for the Wegovy Pill and Ro $498 for Wegovy pens — so mixing them into one column would flatter the compounded prices for the wrong reason.

Every figure here was read off the provider's own pricing page on August 7, 2026, and each row carries that date and a link to the page it came from. Prices in this category move, and several of these providers reserve the right to move them — Mochi's terms say it may change a medication subscription price "at any time for any reason," and Noom's say subscriptions renew "at the price in effect at the time of the renewal." Noom in particular had at least four different figures live across its own site on the day we checked. Read the number on your own checkout screen, not the one on the page that sent you there; if a source disagrees with this page, the source is right and we want to know.